Moderna Soars as Melanoma Vaccine Study Earns Top ESMO Slot

Moderna shares surged 9% to $168 on Monday after its Phase 3 melanoma vaccine study earned the ESMO congress's highest-profile Presidential Symposium slot. The event is scheduled for October 24, where Moderna will present the findings of its adjuvant melanoma study for intismeran autogene, an investigational mRNA individualized neoantigen therapy.

The stock price increase was largely driven by expectation and anticipation of the dataset's significance, rather than any new efficacy data released on Monday. Merck, which co-owns intismeran autogene and supplies pembrolizumab in the study, saw a modest 1% gain, while BioNTech, which runs its own individualized mRNA cancer immunotherapy pipeline, edged up 2%.

The market's reaction to Moderna's announcement suggests that investors view this as a Moderna-specific re-rating, rather than a broader validation of mRNA oncology as a category. The Presidential Symposium slot is typically reserved for datasets expected to change clinical practice, and the presentation on October 24 will be a crucial moment for investors.